Home > Boards > Free Zone > Health and Sciences >

Biotech Values

RSS Feed
      Hide Sticky   Hide Intro
Moderator: DewDiligence Assistants: Biowatch
Search This Board: 
Last Post: 1/24/2020 1:54:28 AM - Followers: 1438 - Board type: Free - Posts Today: 1

Biotech Values is a forum for discussing 
all facets of biotech investing with an emphasis
on fundamental analysis and avoiding scams.
We generally do not discuss microcap stocks.

Compilations
Biotech Buyouts/Premiums
Common Biotech-Newbie Mistakes
Biotech Acronyms

'Way Back' Archive

PostSubject
#228392  Sticky Note I don’t think one needs to listen to jq1234 01/23/20 06:22:07 PM
#228390  Sticky Note EPZM—FDA approves Tazverik (tazemetostat) for epithelioid sarcoma (metastatic DewDiligence 01/23/20 06:05:14 PM
#228358  Sticky Note MGNX: Marg OS benefit (difference) was weak, and miljenko 01/22/20 11:54:26 PM
#228356  Sticky Note On the surface these data look strong and dewophile 01/22/20 04:41:54 PM
#228401   Update data from RCC PIVOT2 (bem v bem+nivo) miljenko 01/24/20 01:54:28 AM
#228400   List price of EPZM’s Tazverik is $186K per DewDiligence 01/23/20 08:03:52 PM
#228399   NKTR—I never heard WL in any previous CC…he DewDiligence 01/23/20 07:38:04 PM
#228398   Pretty much. Current chronic HIV treatment isn’t cure. jq1234 01/23/20 07:11:39 PM
#228397   Got it—very clear now. DewDiligence 01/23/20 07:08:28 PM
#228396   Don’t read these two sentences as directly related. jq1234 01/23/20 06:59:54 PM
#228395   Re: Definition of “functional cure” …undetectable got to DewDiligence 01/23/20 06:42:06 PM
#228394   A little bit, undetectable got to last for jq1234 01/23/20 06:37:28 PM
#228393   NKTR—…you knew CMC issue as major already - DewDiligence 01/23/20 06:34:50 PM
#228392   I don’t think one needs to listen to jq1234 01/23/20 06:22:07 PM
#228391   The goal should be cure or functional cure…Are DewDiligence 01/23/20 06:09:30 PM
#228390   EPZM—FDA approves Tazverik (tazemetostat) for epithelioid sarcoma (metastatic DewDiligence 01/23/20 06:05:14 PM
#228389   The goal should be cure or functional cure, jq1234 01/23/20 05:55:19 PM
#228388   NKTR—I looked at past PIVOT-02 data presentations again, DewDiligence 01/23/20 05:47:38 PM
#228387   GILD is testing its oral PD-L1 inhibitor, GS-4224 DewDiligence 01/23/20 05:42:26 PM
#228386   GILD is testing its oral PD-L1 inhibitor GS-4224 jq1234 01/23/20 05:13:22 PM
#228384   {{Additionally, Forty Seven is evaluating magrolimab for the vinmantoo 01/23/20 04:56:17 PM
#228383   Re FTSV. Clinical data in patients Whalatane 01/23/20 04:16:32 PM
#228382   Never seen anything like Tril Today. vinmantoo 01/23/20 04:13:41 PM
#228381   Re: PD-(L)1 agents for HBV …I don't think DewDiligence 01/23/20 03:51:20 PM
#228380   The infection drives PD-L1 expression in hepatocytes [1]. jondoeuk 01/23/20 03:37:50 PM
#228379   I was starting to think the SE profile dewophile 01/23/20 03:02:32 PM
#228378   Correct re ASMB soaring after dilution: #msg-152763587. DewDiligence 01/23/20 03:01:02 PM
#228377   Never seen anything like Tril Today. dewophile 01/23/20 02:57:20 PM
#228376   Never seen anything like Tril Today. jbog 01/23/20 02:45:46 PM
#228375   PS, I've had my share of Bad Trades also. vinmantoo 01/23/20 02:06:21 PM
#228374   lindtu, They don't have the time or patience to jbog 01/23/20 01:09:05 PM
#228373   It’s fairly common for cash-poor biotechs to rise DewDiligence 01/23/20 12:44:09 PM
#228372   I don't understand why TRIL open mkt price linhdtu 01/23/20 12:41:17 PM
#228371   p.s. VIR’s CEO is George Scangos of BIIB/EXEL DewDiligence 01/23/20 12:40:21 PM
#228370   XENE announces pricing of public offering of common shares bladerunner1717 01/23/20 12:18:21 PM
#228369   Wow, Thats great, they spend it wisely. vinmantoo 01/23/20 11:54:32 AM
#228368   I would assume so. Supplying Cem. miljenko 01/23/20 11:41:18 AM
#228367   It is NIAID study, still waiting to start.So, DewDiligence 01/23/20 11:16:29 AM
#228366   They are not the only one. REGN with miljenko 01/23/20 11:05:21 AM
#228365   Chinese company tests PD-L1 agent in HBV(!?)… DewDiligence 01/23/20 10:44:44 AM
#228364   Folksy shareholder letter from RXMD CEO: DewDiligence 01/23/20 10:35:55 AM
#228363   $TRIL prices $101.7m offering at $2.75/share jbog 01/23/20 08:45:11 AM
#228362   $TRIL prices $101.7m offering at $2.75/share $90m mkt ronpopeil 01/23/20 08:31:06 AM
#228361   Revance price target raised to $39 from $34 jbog 01/23/20 06:47:12 AM
#228360   RVNC- Revance, Amphastar Named Top 2020 Specialty Pharmaceuticals biotech_researcher 01/23/20 05:59:50 AM
#228359   While I expect the normal short term dip vinmantoo 01/23/20 12:22:00 AM
#228358   MGNX: Marg OS benefit (difference) was weak, and miljenko 01/22/20 11:54:26 PM
#228357   TRIL offering jbog 01/22/20 08:44:15 PM
#228356   On the surface these data look strong and dewophile 01/22/20 04:41:54 PM
#228355   TRIL offering ronpopeil 01/22/20 04:14:21 PM
#228354   Dew agree its a long shot but note rogerm 01/22/20 04:13:00 PM
#228353   The data look marginal to me. If you dewophile 01/22/20 03:16:03 PM
#228352   NK. Anyone want to opine on todays price Whalatane 01/22/20 03:16:02 PM
#228351   AXSM—Would the FDA consider a AXS-05 NDA for DewDiligence 01/22/20 02:52:02 PM
PostSubject